Document Detail


Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
MedLine Citation:
PMID:  10417749     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pressure ulcers are associated with significant rates of morbidity and mortality, particularly in the geriatric and spinal cord-injured populations. Newer pharmacologically active therapies include the use of topically applied recombinant human platelet-derived growth factor-BB (becaplermin), the active ingredient in REGRANEX) (becaplermin) Gel 0.01%, which has been approved in the United States for treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. In this study, the efficacy of becaplermin gel in the treatment of chronic full thickness pressure ulcers was compared with that of placebo gel. A total of 124 adults (>/= 18 years of age) with pressure ulcers were assigned randomly to receive topical treatment with becaplermin gel 100 microg/g (n = 31) or 300 microg/g (n = 32) once daily alternated with placebo gel every 12 hours, becaplermin gel 100 microg/g twice daily (n = 30), or placebo (sodium carboxymethylcellulose) gel (n = 31) twice daily until complete healing was achieved or for 16 weeks. All treatment groups received a standardized regimen of good wound care throughout the study period. Study endpoints were the incidence of complete healing, the incidence of >/= 90% healing, and the relative ulcer volume at endpoint (endpoint/baseline). Once-daily treatment of chronic pressure ulcers with becaplermin gel 100 microg/g or 300 microg/g significantly increased the incidences of complete and >/= 90% healing and significantly reduced the median relative ulcer volume at endpoint compared with that of placebo gel (p < 0.025 for all comparisons). Becaplermin gel 300 microg/g did not result in a significantly greater incidence of healing than that observed with 100 microg/g. Treatment with becaplermin gel was generally well tolerated and the incidence of adverse events was similar among treatment groups. In conclusion, once-daily application of becaplermin gel is efficacious in the treatment of chronic full thickness pressure ulcers.
Authors:
R S Rees; M C Robson; J M Smiell; B H Perry
Related Documents :
6490129 - Correlation of blood groups with congenital disorders and gastro intestinal diseases.
25426089 - Effects of positive mood on attentional breadth for emotional stimuli.
25422959 - Maternal prenatal anxiety and child brain-derived neurotrophic factor (bdnf) genotype: ...
17427249 - Stress-ulcer prophylaxis for general medical patients: a review of the evidence.
14687809 - Intragastric ph during continuous infusion with pantoprazole in patients with bleeding ...
7732329 - Meta-analysis of the effect of placebo on the outcome of medically treated reflux esoph...
12395939 - Effects of a multiprofessional rehabilitation programme for patients with fibromyalgia ...
9250729 - The behavioural response to whiplash injury.
23509869 - Patients' perceptions of depression and coronary heart disease: a qualitative upbeat-uk...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society     Volume:  7     ISSN:  1067-1927     ISO Abbreviation:  Wound Repair Regen     Publication Date:    1999 May-Jun
Date Detail:
Created Date:  1999-09-10     Completed Date:  1999-09-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9310939     Medline TA:  Wound Repair Regen     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  141-7     Citation Subset:  IM    
Affiliation:
University of Michigan Medical Center and Department of Veterans Affairs Medical Center, Ann Arbor, USA. rreese@umich.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Cutaneous
Adult
Aged
Anticoagulants / administration & dosage,  adverse effects,  therapeutic use*
Chronic Disease
Double-Blind Method
Female
Gels
Humans
Incidence
Male
Middle Aged
Placebos
Platelet-Derived Growth Factor / administration & dosage,  adverse effects,  therapeutic use*
Pressure Ulcer / drug therapy*
Prospective Studies
Recombinant Proteins
Safety
Wound Healing
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Gels; 0/Placebos; 0/Platelet-Derived Growth Factor; 0/Recombinant Proteins; 0/platelet-derived growth factor BB

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Perspective article: transforming growth factor-beta: crossroad of glucocorticoid and bleomycin regu...
Next Document:  Recombinant adenoviral mediated gene transfer in ischemic impaired wound healing.